Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 108

1.

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.

Mov Disord. 2016 Jul;31(7):1049-54. doi: 10.1002/mds.26569. Epub 2016 Mar 15.

PMID:
26990766
2.

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argilés JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens P, Blennow K, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2015 Sep;138(Pt 9):2701-15. doi: 10.1093/brain/awv199. Epub 2015 Jul 27.

3.

Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.

Tolosa E, Hernández B, Linazasoro G, López-Lozano JJ, Mir P, Marey J, Kulisevsky J.

J Neural Transm (Vienna). 2014 Apr;121(4):357-66. doi: 10.1007/s00702-013-1114-x. Epub 2013 Nov 20.

PMID:
24253234
4.

Lewy bodies under atomic force microscope.

Tercjak A, Bergareche A, Caballero C, Tuñon T, Linazasoro G.

Ultrastruct Pathol. 2014 Feb;38(1):1-5. doi: 10.3109/01913123.2013.825689. Epub 2013 Oct 17.

PMID:
24134525
5.

Neuroprotective role of dopamine agonists: evidence from animal models and clinical studies.

Herrero MT, Pagonabarraga J, Linazasoro G.

Neurologist. 2011 Nov;17(6 Suppl 1):S54-66. doi: 10.1097/NRL.0b013e31823968fc. Review.

PMID:
22045327
6.

Dopaminergic agonists in Parkinson's disease.

Alonso Cánovas A, Luquin Piudo R, García Ruiz-Espiga P, Burguera JA, Campos Arillo V, Castro A, Linazasoro G, López Del Val J, Vela L, Martínez Castrillo JC.

Neurologia. 2014 May;29(4):230-41. doi: 10.1016/j.nrl.2011.04.012. Epub 2011 Jul 2. Review. English, Spanish.

7.

Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats.

Morera-Herreras T, Ruiz-Ortega JA, Linazasoro G, Ugedo L.

Psychopharmacology (Berl). 2011 Mar;214(2):379-89. doi: 10.1007/s00213-010-2043-0. Epub 2010 Oct 20.

8.

Classifying risk factors for dyskinesia in Parkinson's disease.

Sharma JC, Bachmann CG, Linazasoro G.

Parkinsonism Relat Disord. 2010 Sep;16(8):490-7. doi: 10.1016/j.parkreldis.2010.06.003. Epub 2010 Jul 3. Review.

PMID:
20598622
9.

Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study.

Linazasoro G, Van Blercom N, Bergaretxe A, Iñaki FM, Laborda E, Ruiz Ortega JA.

Clin Neuropharmacol. 2009 Nov-Dec;32(6):326-9. doi: 10.1097/WNF.0b013e3181b52792.

PMID:
19855268
10.

Efficacy and safety of pallidal stimulation in primary dystonia: results of the Spanish multicentric study.

Valldeoriola F, Regidor I, Mínguez-Castellanos A, Lezcano E, García-Ruiz P, Rojo A, Salvador A, Castro A, Grandas F, Kulisevsky J, Martí MJ, Martínez-Martín P, Relova L, Rumià J, Cámara A, Burguera JA, Linazasoro G, de Val JL, Obeso J, Rodríguez-Oroz MC, Tolosa E; Grupo ESpañol para el EStudio de la EStimulación PALidal en la DIStonía.

J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):65-9. doi: 10.1136/jnnp.2009.174342. Epub 2009 Sep 10.

PMID:
19744963
11.

A global view of Parkinson's disease pathogenesis: implications for natural history and neuroprotection.

Linazasoro G.

Parkinsonism Relat Disord. 2009 Jul;15(6):401-5. doi: 10.1016/j.parkreldis.2009.02.011. Epub 2009 Apr 5.

PMID:
19346152
12.

[Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].

Linazasoro G, Sesar A, Valldeoriola F, Compta Y, Herrero MT, Martínez Castrillo JC, López Lozano JJ, Bergaretxe A, Vela L, Fernández JM, Castro A, Kulisevski J, Lezcano E, Vaamonde J, López Del Val J, Chacón J, Vivancos F, Luquin R, Aguilar M, Burguera JA, Salvador C, Menéndez Guisasola L, Catalán MJ, Mir P, Campos V, Grandas F, Mínguez A, Balaguer E, Yáñez R, Leiva C, García Ruiz P, Cubo E.

Neurologia. 2009 Mar;24(2):113-24. Spanish.

PMID:
19322690
13.

Dopamine dysregulation syndrome and levodopa-induced dyskinesias in Parkinson disease: common consequences of anomalous forms of neural plasticity.

Linazasoro G.

Clin Neuropharmacol. 2009 Jan-Feb;32(1):22-7. doi: 10.1097/WNF.0B013E3181634EA6.

PMID:
18978500
14.

Pathogenesis of PD: missing the point.

Linazasoro G.

Mov Disord. 2010 Jan 15;25(1):122-3. doi: 10.1002/mds.22327. No abstract available.

PMID:
18823028
15.

[If I were to wake up clumsy and shaking (10 years later)].

Linazasoro G.

Neurologia. 2008 Sep;23(7):449-55. Review. Spanish.

PMID:
18726723
16.

Acute dystonia in a young schizophrenic patient associated with ingestion of a cloperastine containing cough syrup.

Linazasoro G, Garmendia MT, Lizaso X.

Parkinsonism Relat Disord. 2000 Jan;6(1):57-8.

PMID:
18591150
17.

[Spinal cord compression due to a epidural lipoma].

Urculo E, Samprón N, Alfaro R, Arrazola M, Linazasoro G.

Neurocirugia (Astur). 2008 Apr;19(2):156-60. Spanish.

18.

Imaging beta-amyloid burden in aging and dementia.

Linazasoro G.

Neurology. 2008 Apr 29;70(18):1649; author reply 1650. doi: 10.1212/01.wnl.0000318046.06992.24. No abstract available.

PMID:
18443321
19.

Potential applications of nanotechnologies to Parkinson's disease therapy.

Linazasoro G; Nanotechnologies for Neurodegenerative Diseases Study Group of the Basque Country (NANEDIS).

Parkinsonism Relat Disord. 2008;14(5):383-92. doi: 10.1016/j.parkreldis.2007.11.012. Epub 2008 Mar 7. Review.

PMID:
18329315
20.

[Rasagiline in Parkinson's disease].

Linazasoro G.

Neurologia. 2008 May;23(4):238-45. Review. Spanish.

PMID:
18307054

Supplemental Content

Loading ...
Support Center